Fig. 1: Treatment and outcome details of patients.
From: Combined emapalumab and ruxolitinib in patients with haemophagocytic Lymphohistiocytosis
A Overall response of patients. Percentages of patients with a complete response, partial response, or improvement in measures of haemophagocytic lymphohistiocytosis among the previously treated patients and treatment-naive patients. B Estimates of the probability of survival until HSCT. C Estimates of the probability of overall survival. D Levels of Interferon-γ before and after ruxolitinib and emapalumab treatment. E Interleukin-6 concentration. F Interleukin-10 concentration. The decline in IFN-γ was not associated with disease response. Instead, the decrease in IL-6 and IL-10 correlated with the therapeutic effect: decreased IL-6 levels were associated with a response (p = 0.008) and remission (p = 0.025), and decreased IL-10 levels were associated with remission (p = 0.007) but not a response (p = 0.066).
